Among these, targets such as human epidermal growth factor receptor 2 (HER2) in certain types of sarcomas, breast, gastric and ovarian cancers (NCT00902044, NCT04995003 and NCT04511871), cleaved Mucin1 in metastatic breast cancer (NCT04020575), mesothelin in pancreatic and ovarian cancers, and disialoganglioside (GD2) in neuroblastoma (NCT03373097) have attracted considerable interest (22). This evidence concerns the gene MSLN and ovarian carcinoma.